Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

Inclusion Criteria: * Be male or female, ≥18 and ≤80 years of age who have had symptoms of bladder pain in addition to urinary urgency and/or urinary frequency for more than 6 months * Have had a clinical diagnosis, or history consistent with the diagnosis, of interstitial cystitis/bladder pain syndrome for \>3 months but ≤20 years * Must be capable of voiding independently * Have undergone a cystoscopy within the last 36 months prior to Baseline * Women of child bearing potential must have a negative pregnancy test, be non-lactating and agree to avoid pregnancy and use a highly effective method of contraception with one additional barrier method of contraception from screening until at least 28 days after the last dose of study drug has been taken * Men must use a condom for sexual intercourse from screening until at least 90 days after last dose of study drug has been taken, unless they have been surgically sterilized (vasectomy) Exclusion Criteria * Have had a urinary tract infection (UTI) including bacterial cystitis within the past 30 days * Microscopic hematuria that has not been adequately evaluated as per local standard of care * Have a history of chronic substance abuse, dependency or abuse of opiates, or other narcotics within the last 2 years * History of previous procedure(s) (augmentation cystoplasty, cystectomy, cytolysis, botulinum toxin or bladder catheterization) that has significantly affected bladder function * History of cyclophosphamide or chemical cys…